Table Graph
   

chloroquine and derivatives - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.71 [0.25, 2.02]< 10%3 studies (3/-)73.7 %some concernnot evaluable moderatecrucial-
hospitalization 1.00 [0.10, 9.70]< 10%2 studies (2/-)49.8 %lownot evaluable highimportant-
symptomatic Covid-19 0.90 [0.66, 1.23]< 128%5 studies (5/-)74.6 %lownot evaluable highimportant-
asymptomatic COVID case 0.96 [0.49, 1.90]< 10%1 study (1/-)54.4 %NAnot evaluable non important-
infection (PCR positive symptomatic or not) 0.86 [0.69, 1.06]< 10%8 studies (8/-)91.8 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.91 [0.47, 1.76]< 10%3 studies (3/-)60.9 %some concernnot evaluable moderateimportant-
adverse events 3.27 [1.08, 9.95]< 198%5 studies (5/-)1.9 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons